DISPUR, 30th Oct: India’s biggest pharmaceutical company is facing an uncomfortable regulatory battle. Drug authorities have ordered Sun Pharmaceutical Industries to stop manufacturing, selling and distributing ophthalmic products from its Assam facility after inspectors identified failures in its quality management system.

The Sun Pharma eye drops recall has now escalated into a major manufacturing shutdown, raising fresh questions about pharmaceutical quality controls and patient safety.

India’s pharmaceutical industry doesn’t need another quality controversy. And this one deserves serious attention.

Sun Pharma Faces Regulatory Action Over Quality Failures

The Central Drugs Standard Control Organisation (CDSCO) and the office of Drugs Controller Assam ordered the shutdown on August 20, following a joint inspection of Sun Pharma’s manufacturing facility in Assam.

The inspection identified shortcomings in the quality management system responsible for ensuring that pharmaceutical products meet required safety and quality standards.

The development followed the company’s decision in July to voluntarily recall approximately 11 ophthalmic brands.

The regulators had already issued a show-cause notice to Sun Pharma on August 10, citing deficiencies in its quality management system. However, they were dissatisfied with the company’s response.

The subsequent order stopped manufacturing, selling and distributing all ophthalmic products from the facility.

There is a clear distinction here. This is not merely a routine product recall. Regulators have imposed a wider manufacturing restriction, and production cannot resume until the company submits a satisfactory compliance report.

332 Batches Under Regulatory Scrutiny

One of the most significant details concerns the scale of the recall.

Documents reviewed by Reuters show that regulators sought additional information regarding the recall of 332 batches of ophthalmic suspension products. These are liquid formulations used to treat various eye conditions.

The products reportedly included:

• Lotepred 1% 5ml eye drops
• Nepalact OD eye drops
• Nepalact-Z
• Brinzotim eye drops 5ml
• Depopred 2ml

Doctors prescribe these products for conditions involving eye inflammation, infections and chronic eye diseases.

Sun Pharma reportedly described the withdrawal as a precautionary measure in an internal notice sent to stockists.

However, the company did not publicly disclose detailed information about the recall.

More importantly, it remains unclear whether all the recalled products were contaminated. Reuters also could not independently establish whether the 332 batches covered only the 11 identified brands or included additional products.

Industry experts indicated that the affected batches could represent hundreds of thousands of eye-drop bottles.

That is a substantial number of products potentially involved in a quality-related withdrawal.

What Happened at the Assam Manufacturing Facility?

Most of the recalled products identified by Reuters appeared to have been manufactured at Sun Pharma’s Assam facility in Kokjhar village, based on their packaging.

The facility was previously positioned as an important part of the company’s manufacturing expansion.

Sun Pharma had said the site was expected to become one of its largest manufacturing hubs for sterile products. The segment is also considered an important global growth driver for the company.

The regulatory restrictions now create an operational challenge.

The company has submitted a compliance report following the shutdown order. An official familiar with the matter told Reuters that regulators are reviewing the submission.

Until the authorities accept the compliance report, the manufacturing restriction remains in place.

Sun Pharma did not respond to Reuters’ requests for comment on the Assam facility and the product recall.

Eye Drug Safety Raises Wider Concerns in India

The Sun Pharma eye drops recall comes against the backdrop of increased scrutiny of India’s pharmaceutical manufacturing standards.

India has faced domestic and international criticism following incidents involving locally manufactured cough syrups linked to children’s deaths in India, Gambia and Uzbekistan.

The latest development adds another uncomfortable chapter to the debate surrounding pharmaceutical quality assurance.

There was also a related warning from the All India Ophthalmological Society (AIOS), an independent organisation representing eye specialists.

In June, the organisation issued a patient-safety advisory after certain batches of Predmet eye drops appeared to be contaminated.

AIOS secretary and doctor Santosh Honavar told Reuters that infections had been reported among patients who used the product.

He said sealed bottles were subsequently investigated and found to be contaminated. Sun Pharma had also recalled the affected Predmet drops, according to Honavar.

However, the company did not respond to Reuters’ request for comment on the AIOS advisory.

Regulators did not issue a public health alert following the recall, according to the report.

The Bigger Business Impact on Sun Pharma

The regulatory action also carries commercial implications.

Ophthalmology accounts for approximately 3% of Sun Pharma’s domestic revenue, according to its 2025-26 annual report. The segment is also an important business area for the company in the United States.

The Assam facility’s shutdown could therefore complicate an area that Sun Pharma considers strategically important.

The timing is hardly ideal.

On October 30, the company reported a decline in second-quarter profit, partly weighed down by a one-time charge associated with its acquisition of US-based Organon.

The company is now dealing with additional scrutiny over its ophthalmic manufacturing operations.

This is not the first time its sterile manufacturing facilities have attracted regulatory attention.

In 2025, the US Food and Drug Administration halted shipments from Sun Pharma’s Halol facility in Gujarat after inspectors identified shortcomings in contamination controls.

That earlier action and the latest Assam restrictions make manufacturing quality an important issue for the pharmaceutical major.

What Happens Next?

For now, the immediate question is whether regulators will accept Sun Pharma’s compliance report.

The company must demonstrate that the shortcomings identified during the inspection have been adequately addressed.

There are also unanswered questions about the 332 recalled batches, the possibility of contamination, the geographical distribution of the products and whether patients experienced adverse effects.

Reuters could not establish whether the recalled eye products were exported from India or whether patients reported adverse reactions.

These details matter.

A product recall is a preventive measure. A manufacturing shutdown, meanwhile, signals that regulators have identified concerns serious enough to restrict operations.

Sun Pharma now has to address those concerns and restore regulatory confidence.

For a pharmaceutical company operating across international markets, quality assurance cannot be treated as an administrative formality. It is fundamental to the business.

And when the products in question go into people’s eyes, there is very little room for error.

India’s pharmaceutical industry has built a formidable global reputation. But that reputation cannot survive on exports, scale and market leadership alone. It needs uncompromising quality control.

The Sun Pharma eye drops recall deserves attention not because a major company has encountered regulatory trouble, but because ophthalmic medicines directly affect patient safety. Regulators must demand transparent explanations, companies must disclose relevant recall information, and corrective measures must be independently assessed.

Sun Pharma also needs to demonstrate that the problems identified at its Assam facility have been addressed. A compliance report is a necessary step, not the end of the story.

@shivendraedits